share_log

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

查丹资本重申买入 Orchestra BioMed Holdgs,维持20美元的目标股价
Benzinga ·  2023/05/15 04:29

Chardan Capital analyst Keay Nakae reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Chardan Capital分析师Keay Nakae重申Orchestra BioMed Hldgs(纳斯达克股票代码:OBIO)的买入并维持20美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发